Episode Details

Scientists at the University of Wisconsin-Madison have cracked a major manufacturing hurdle for cancer drugs by inventing a simpler, more precise way to make antibody-drug conjugates. Their breakthrough replaces clunky, multi-step methods with a two-step process that creates a uniform, highly targeted drug capable of killing cancer cells while sparing healthy ones. The innovation stems from tweaking antibodies’ natural sugar structures to carry payloads — a clever twist that also opens doors for treating other diseases. Already, a startup called GlycoBridge Biosciences is being formed to scale this tech, with early funding and industry partnerships in place to accelerate next-gen therapies.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/817743fa10d3c003